Outcome According to Treatment Group
| . | % Probability (95% confidence interval) . | Significance . | |||
|---|---|---|---|---|---|
| Study (1) . | Historic (2) . | CyA/MTX (3) . | P12 . | P13 . | |
| 0.5 × 109 neutrophils/L | .84 | <.0001 | |||
| By day 21 | 23 (14, 34) | 50 (36, 64) | 59 (55, 64) | ||
| By day 30 | 78 (67, 87) | 70 (57, 82) | 93 (90, 95) | ||
| By day 60 | 94 (87, 98) | 83 (71, 92) | 99 (97, 100) | ||
| Graft failure | .0003 | .03 | |||
| At 1 mo | 4 (1, 11) | 20 (10, 32) | 1 (0, 3) | ||
| At 12 mo | 6 (2, 13) | 31 (19, 45) | 2 (1, 3) | ||
| Acute GVHD | |||||
| Grade II-IV | 4 | 20 | 35 | .01 | <.001 |
| Chronic GVHD | |||||
| Grade I-IV (limited-extensive) | 3 | 21 | 36 | .005 | <.001 |
| Transplant-related mortality | <.0001 | .06 | |||
| At 3 yrs | 15 (7, 25) | 53 (38, 67) | 25 (21, 29) | ||
| At 5 yrs | 15 (7, 25) | 58 (43, 72) | 26 (22, 31) | ||
| Relapse | .54 | .67 | |||
| At 3 yrs | 27 (17, 39) | 22 (9, 38) | 24 (20, 29) | ||
| At 5 yrs | 30 (19, 42) | 22 (9, 38) | 29 (24, 35) | ||
| Survival | .001 | .27 | |||
| At 3 yrs | 65 (53, 76) | 39 (26, 53) | 59 (55, 64) | ||
| At 5 yrs | 62 (50, 74) | 35 (22, 49) | 58 (53, 62) | ||
| Leukemia-free survival | .002 | .24 | |||
| At 3 yrs | 62 (50, 73) | 37 (24, 51) | 57 (52, 62) | ||
| At 5 yrs | 60 (47, 71) | 33 (21, 47) | 52 (47, 57) | ||
| . | % Probability (95% confidence interval) . | Significance . | |||
|---|---|---|---|---|---|
| Study (1) . | Historic (2) . | CyA/MTX (3) . | P12 . | P13 . | |
| 0.5 × 109 neutrophils/L | .84 | <.0001 | |||
| By day 21 | 23 (14, 34) | 50 (36, 64) | 59 (55, 64) | ||
| By day 30 | 78 (67, 87) | 70 (57, 82) | 93 (90, 95) | ||
| By day 60 | 94 (87, 98) | 83 (71, 92) | 99 (97, 100) | ||
| Graft failure | .0003 | .03 | |||
| At 1 mo | 4 (1, 11) | 20 (10, 32) | 1 (0, 3) | ||
| At 12 mo | 6 (2, 13) | 31 (19, 45) | 2 (1, 3) | ||
| Acute GVHD | |||||
| Grade II-IV | 4 | 20 | 35 | .01 | <.001 |
| Chronic GVHD | |||||
| Grade I-IV (limited-extensive) | 3 | 21 | 36 | .005 | <.001 |
| Transplant-related mortality | <.0001 | .06 | |||
| At 3 yrs | 15 (7, 25) | 53 (38, 67) | 25 (21, 29) | ||
| At 5 yrs | 15 (7, 25) | 58 (43, 72) | 26 (22, 31) | ||
| Relapse | .54 | .67 | |||
| At 3 yrs | 27 (17, 39) | 22 (9, 38) | 24 (20, 29) | ||
| At 5 yrs | 30 (19, 42) | 22 (9, 38) | 29 (24, 35) | ||
| Survival | .001 | .27 | |||
| At 3 yrs | 65 (53, 76) | 39 (26, 53) | 59 (55, 64) | ||
| At 5 yrs | 62 (50, 74) | 35 (22, 49) | 58 (53, 62) | ||
| Leukemia-free survival | .002 | .24 | |||
| At 3 yrs | 62 (50, 73) | 37 (24, 51) | 57 (52, 62) | ||
| At 5 yrs | 60 (47, 71) | 33 (21, 47) | 52 (47, 57) | ||
The outcome is reported, together with the 95% confidence interval. Significance (P) values in this table (except for GVHD) were calculated from a univariate long-rank test (ie, they do not take into account any potential covariates).